Characteristic | Freq. (%) | ||
---|---|---|---|
Dose-dense regimen (n = 69) | Conventional regimen (n = 138) | pa | |
Age | |||
Median (P25–75) | 52.6 (45.5–59.1) | 54.8 (47.3–61.3) | 0.290 |
≤ 65 | 64 (92.8) | 128 (92.8) | 1.000 |
> 65 | 5 (7.2) | 10 (7.2) | |
FIGO stage | |||
I -II | 5 (7.2) | 10 (7.2) | 1.000 |
III-IV | 64 (92.8) | 128 (92.8) | |
Histology | |||
High-grade serous carcinoma | 61 (88.4) | 111 (80.4) | 0.149 |
Others | 8 (11.6) | 27 (19.6) | |
ECOG performance status | |||
0 | 45 (65.2) | 79 (57.2) | 0.134 |
≥ 1 | 21 (30.4) | 59 (42.8) | |
Missing data | 3 (4.3) | 0 (0) | |
CA125 | |||
Median (P25–75) | 344 (72.8–1427) | 392.8 (97–1470.2) | 0.614 |
≤ 200 | 29 (42) | 52 (37.7) | 0.442 |
> 200 | 38 (55.1) | 86 (62.3) | |
Missing data | 2 (2.9) | 0 (0) | |
Type of cytoreductive surgery | |||
Primary | 48 (69.6) | 92 (66.7) | 0.674 |
Interval | 21 (30.4) | 46 (33.3) | |
Complete cytoreduction | |||
Yes | 61 (88.4) | 120 (87) | 0.570 |
No | 7 (10.1) | 18 (13) | |
Missing data | 1 (1.4) | 0 (0) | |
BRCA1/2 mutation | |||
Yes | 14 (20.3) | 11 (8) | 0.793 |
No | 44 (63.9) | 39 (28.2) | |
Missing data | 11 (15.9) | 88 (63.8) | |
Family history of breast or ovarian cancer | |||
Yes | 21 (30.4) | 46 (33.4) | 0.778 |
No | 43 (62.4) | 86 (62.3) | |
Missing data | 5 (7.2) | 6 (4.3) |